Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post-Marketing Surveillance of Perjeta in Breast Cancer

Trial Profile

Post-Marketing Surveillance of Perjeta in Breast Cancer

Phase of Trial: Phase IV

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs Pertuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 02 Apr 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 24 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top